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Purpose or Objective : Unwanted peripheral doses (PD) from 
external beam radiotherapy (RT) are associated with 
increased incidence of second cancers. PD estimations after 
RT are becoming highly relevant due to the larger cancer 
incidence as well as survival rates. Additionally, an accurate 
knowledge of out-of-field doses is of importance when 
treating children, pregnant patients and those with 
implantable electronic devices [1]. Our group has developed 
a novel peripheral photon dose (PPD) model [2] which 
includes intensity modulated treatments. This model 
estimates out-of-field doses (i.e., beyond the commercial 
TPS limits -around 10 cm from the field edge) received by 
individual patients undergoing any RT isocentric technique.  
The aim of this work was the experimental validation of the 
model in a number of points inside the Alderson Radiation 
Therapy phantom (ART) irradiated with an IMRT prostate 
plan. This exercise is part of the process toward the 
implementation of the model onto a commercial TPS. 
 
Material and Methods: A Siemens Primus linac was used to 
deliver a 6 MV prostate IMRT treatment (896 MU and 7 
incidences, equivalent to 2 fractions of the treatment). TLD-
100 pairs of dosimeters were inserted at phantom holders, 
placed outside the 1% isodose as shown in the coronal plane 
of the figure. Positions were selected as being representative 
of cancer-at-risk organs. TLD-100 readings were converted 
into doses, through a calibration factor which considers the 
spectral condition outside the field, and then compared to 
PPD model estimates [2]. Measured leakage outside the field 
resulted 4 μGy/MU. Peripheral photon equivalent dose (PPED) 
to organs was also computed using PERIPHOCAL [2] (a 
MATLAB® GUI piece of software which considers a basic 
patient model with scaled dimensions from Cristy phantom 
[3]).  
 
Results: Plot at the figure depicts the estimated and 
measured photon equivalent doses (mSv) at 11 points for 
studied case (identified on the coronal plane of the 
phantom). Uncertainty Range (UR) corresponds to ±2 mSv and 
the error bars represent the ±6 % global uncertainty 
estimated for the TLDs in the out-of-field area2.  
Figure. 
 
 
Conclusion: Validation of a PPD calculation model [2] has 
been carried out in an Alderson phantom for an IMRT prostate 
treatment using TLD-100 detectors. Very good agreement has 
been found between the model and the experimental 
measurements. However, bigger differences have been found 
between dose to points and PPED to organs, which might 
suggests that the mathematical phantom and/or the 
escalation model used for estimating organ 
location/dimensions are not properly mimicking the anatomy 
of the Alderson phantom. This issue deserves further 
investigation before implementing the dose-to-organ model 
onto a commercial TPS. 
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Purpose or Objective: Flattening filter free (FFF) beams 
generated by medical linacs are today clinically used for 
stereotactical treatments, thanks to their very high dose rate 
(up to four times the dose rate of the common flattened 
beams). Such beams differ from the standard flattened 
beams (FF) in the profile shape, that is strongly peaked on 
the beam central axis. However, FFF beams are not standard 
in terms of the parameters describing the field 
characteristics. Definitions of new parameters as unflatness 
and slope for FFF beams have been proposed, based on a 
renormalization factor for FFF profiles. With those factors 
the FFF dose fall-off at the field edge is superimposed with 
the corresponding (in nominal energy) flattened profile 
commonly normalized to 100% at the beam central axis. The 
present study aims to provide the renormalization factors for 
FFF beams of 6 and 10 MV generated by Varian TrueBeam and 
by Elekta Versa HD linacs. Estimation of the values of the 
new parameters (unflatness and slope) for the two units are 
also given. 
 
Material and Methods: Dosimetric data from two Varian 
TrueBeam and two Elekta Versa HD linacs, all with 6 and 10 
MV nominal accelerating potentials, FF and FFF modes have 
been collected. Renormalization factors were estimated 
according to Fogliata et al. procedure (Med.Phys. 2012,39) 
with the third derivative method, and parameters of 
RenormFactor=(a+b*FS+c*depth)/(1+d*FS+e*depth) have been 
fitted for FFF beams of both units and energies. Unflatness 
and slope parameters were computed. Dosimetric differences 
as beam penetration and surface dose were also assessed. 
 
Results: Renormalization factors are summarized in the 
graphs here presented. 
 
 
 
Once the FFF profiles have been renormalized, the unflatness 
and slope were computed. As an example of unflatness 
parameter, for a 20x20 cm2 field, it was estimated in the 
range (from dmax to 30 cm depth) of 1.248-1.317, and 1.304-
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1.371 for the 6MV beams, TrueBeam and Versa HD, 
respectively. The same figure for the 10MV beams were 
1.484-1.524, and 1.501-1.543. Concerning beam penetration, 
TPR20,10 for 6 and 10 flattened and FFF TrueBeam beams 
were: 0.665, 0.629 (6MV) and 0.738, 0.703 (10MV), while for 
Versa HD beams are: 0.684, 0.678 (6MV) and 0.734, 0.721 
(10MV). 
 
Conclusion: Renormalization factor and unflatness 
parameters proved to be efficient to describe the FFF beam 
characteristics. Renormalization factors here presented could 
be used for all TrueBeam and Versa HD beams, without the 
need of recalculate them for the site specific conditions. 
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Purpose or Objective: Monte Carlo calculations are 
increasingly applied as an independent QA tool for pre-
treatment verification of patient plans for complex 
treatment delivery techniques such as VMAT. The dose 
obtained is usually imported to the treatment planning 
system for further analysis. The analysis can encompass 
visual comparison of dose distributions as well as qualitative 
and/or quantitative comparison of Dose Volume Histograms 
for specific structures. More sophisticated quantitative 
comparison in 3D includes gamma analysis combining dose 
difference and distance-to-agreement evaluation generating 
pass/fail maps. The normalized dose difference (NDD) 
method is considered to be an extension of the gamma-index 
concept including locally defined, spatially varying 
normalization factors. The NDD is reported to be insensitive 
to the dose grid size. Also, it shows which dose distribution 
has a higher value at the comparison point (has a sign).  
The objective of the work is to test the applicability of the 
NDD method in the Monte Carlo pre-treatment QA procedure, 
as well as to develop a stand-alone module which will include 
visual and quantitative analysis. 
 
Material and Methods: Monte Carlo simulations were 
performed using the EGSnrc/BEAMnrc code system with 
modifications, capable to compute dose distributions due to 
a continuously moving gantry, dynamic multileaf collimator 
and variable dose rate (I.A. Popescu and J. Lobo, Radiother. 
Onc.2007). A Monte Carlo model of a Varian Clinac iX 
accelerator was used. Patient treatment plans were 
generated by Eclipse treatment planning system (Varian 
Medical Systems, USA) and calculated by the AAA algorithm. 
NDD formalism has been applied in Matlab (Mathworks®) as 
described in (Jiang SB, et al. Phys Med Biol 2006). 
 
Results: Dose distributions for patients in different 
anatomical regions have been obtained; pelvic and head and 
neck. Example of NDD analysis for a prostate cancer is shown 
in the figure.  
 
 
 
A 3%, 3 mm tolerance criteria is used. The colour scale varies 
from ±3%, i.e. the region of acceptance. Negative values 
indicate that the Eclipse dose (AAA) is lower than the Monte 
Carlo calculated dose. The Monte Carlo simulations include 
the air surrounding the patient. Therefore the NDD values 
outside the patient are negative. All the NDD values are 
within tolerance on the left transversal slice, i.e. there is 
agreement between Monte Carlo and AAA. On the right 
transversal slice, the AAA shows higher target dose in small 
ventral regions and lower dose at some points in the risk 
organ (rectum). In general the pass-rate observed is > 95%. A 
slight dominance of the Monte Carlo dose has been observed 
in the NDD statistics expressed as a shift of the maximum in 
the NDD distribution. 
 
Conclusion: The NDD method can give important information 
for pre-treatment verification of VMAT plans, which is 
complementary to the dose analysis in the treatment 
planning system. 
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Purpose or Objective: To evaluate the usefulness and 
accuracy of a commercially available plastic scintillator 
(Exradin W1) for use in in vivo proton therapy skin dosimetry. 
 
Material and Methods: Six patients undergoing passive 
scatter proton therapy for prostate cancer were enrolled in 
an IRB approved protocol. The Exradin W1 plastic scintillator 
was used to measure in vivo skin dose by attaching the 
detector to the patient’s skin at the central axis of each 
treatment field (2 laterally opposed treatment fields). 
Measurements were acquired once per week for the entire 
treatment course resulting in a total of 93 measurements. 
The detector was first calibrated on a Cobalt-60 unit, and 
phantom measurements in the proton beam with the W1 and 
a calibrated parallel plane ion chamber were used to account 
for the under-response due to ionization quenching. The 
average dose difference between the Exradin W1 in vivo dose 
and parallel plane ion chamber in phantom dose over all 
measurement and per-patient was computed, as well as 
standard deviations. Furthermore, dose extracted from the 
treatment planning system was compare to the parallel plane 
ion chamber. Finally, baseline stability measurements in the 
cobalt unit were performed weekly for the duration of the 
study. 
 
Results: The calibrated detector exhibited a 7% under-
response for 225 MeV proton beams. The temperature under-
response was 4% when used at 37° C (relative to the response 
at the calibration temperature of 20° C). The detector 
exhibited a stable response and was within 1% for the 
duration of the study (144 days). The average dose difference 
between the Exradin W1 and parallel plane ion chamber over 
all patient measurements was 0.27 ± 0.67% after applying the 
temperature and quenching correction factors. The dose 
difference between the Exradin W1 in vivo measurements 
and parallel plane ion chamber for all six patients treatment 
fields throughout the study were all within ± 2% with a 
standard deviation of 0.67% (see figure 1). 
 
Figure 1 Dose difference between Exradin W1 in vivo dose 
and parallel plane ion chamber dose for every patient during 
the study. 
 
